Charming Medical Income Statement

Financials in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023
Revenue	6.22	6.02	3.53
Revenue Growth (YoY)	3.43%	70.37%	-
Cost of Revenue	0.2	0.17	0.05
Gross Profit	6.02	5.84	3.48
Selling, General & Admin	4.16	4.28	3.65
Operating Expenses	4.42	4.67	3.86
Operating Income	1.6	1.17	-0.38
Interest Expense	-0.02	-0.03	-0.02
Interest & Investment Income	0.06	0.02	0.01
Other Non Operating Income (Expenses)	-0.21	-0.16	-0.03
EBT Excluding Unusual Items	1.43	1	-0.42
Gain (Loss) on Sale of Investments	0	-	-
Pretax Income	1.44	1	-0.42
Income Tax Expense	0.24	0.18	-0.08
Earnings From Continuing Operations	1.2	0.82	-0.34
Minority Interest in Earnings	-	-0.04	0.03
Net Income	1.2	0.78	-0.31
Net Income to Common	1.2	0.78	-0.31
Net Income Growth	54.16%	-	-
Shares Outstanding (Basic)	15	15	15
Shares Outstanding (Diluted)	15	15	15
EPS (Basic)	0.08	0.05	-0.02
EPS (Diluted)	0.08	0.05	-0.02
EPS Growth	54.16%	-	-
Free Cash Flow	0.14	0.08	1.83
Free Cash Flow Per Share	0.01	0.01	0.12
Gross Margin	96.76%	97.17%	98.66%
Operating Margin	25.71%	19.49%	-10.73%
Profit Margin	19.27%	12.93%	-8.64%
Free Cash Flow Margin	2.22%	1.41%	51.76%
EBITDA	1.86	1.56	-0.17
EBITDA Margin	29.95%	26.00%	-4.76%
D&A For EBITDA	0.26	0.39	0.21
EBIT	1.6	1.17	-0.38
EBIT Margin	25.71%	19.49%	-10.73%
Effective Tax Rate	16.45%	18.11%	-
Revenue as Reported	6.22	6.02	3.53
Advertising Expenses	1	0.86	0.66

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q